Postoperative nausea and vomiting (PONV) is consistently rated by patients as one of the most unpleasant aspects of any operative procedure 1,2 . Its occurrence may negatively impact on the satisfaction with medical care 3,4 , have economic implications in terms of increased length-of-stay in the post-anaesthesia care unit and hospital 5,6 , and occasionally result in serious complications 7,8 . Multiple risk factors for PONV have been described encompassing patient-, surgical-and anaesthesiarelated domains 9-12 . Apfel et al developed a simplified risk score for the development of PONV using four of these risk factors, which has proven utility in guiding prophylactic antiemetic therapy 10 . However, the consistent assessment of what is clinically important PONV has been more difficult.
Postoperative nausea and vomiting (PONV) is consistently rated by patients as one of the most unpleasant aspects of any operative procedure 1, 2 . Its occurrence may negatively impact on the satisfaction with medical care 3, 4 , have economic implications in terms of increased length-of-stay in the post-anaesthesia care unit and hospital 5, 6 , and occasionally result in serious complications 7, 8 . Multiple risk factors for PONV have been described encompassing patient-, surgical-and anaesthesiarelated domains [9] [10] [11] [12] . Apfel et al developed a simplified risk score for the development of PONV using four of these risk factors, which has proven utility in guiding prophylactic antiemetic therapy 10 . However, the consistent assessment of what is clinically important PONV has been more difficult.
Recently, Wengritzky et al 13 developed and tested a PONV Intensity Scale (Appendix) which aims to better quantify clinically important PONV. Briefly, the PONV Intensity Scale was developed in consultation with perioperative clinical staff, patients and patients' families. The scale defined clinically important PONV as a score greater than 50, which was achieved either with more than three vomits (stand alone significant criteria), or a nausea and vomiting experience with a combined intensity that was significant to all stakeholders in the PONV Intensity Scale's development. This score was developed and tested in a general surgical population and performed well in the domains of validity, reliability and responsiveness 13 . In this study, we aimed to extend the evaluation of the PONV Intensity Scale to a gynaecological surgery population who may be at high risk of PONV. Our hypothesis was that the PONV Intensity Scale would be valid and responsive, and have practical utility in this clinical and research setting.
Additionally, consensus guidelines on the management of PONV have been published in SUMMARY The Postoperative Nausea and Vomiting (PONV) Intensity Scale was developed to distinguish trivial from clinically important PONV perioperatively and has been validated in a general surgical population. This study aimed to assess the scale in gynaecological surgery patients.
Seventy-three patients undergoing gynaecological surgery were included. Interviews occurred at four and 24 hours postoperatively. Measurements included the PONV Intensity Scale, nausea and pain visual analogue scale, antiemetic use and complications related to PONV.
Ten patients (14%) had a clinically significant PONV Intensity Scale score, 42 (58%) reported nausea and 15 (21%) reported vomiting during the study. At 24 hours, 80% of patients with a clinically significant score at four hours had received antiemetics vs 18% of those without a clinically significant score (P=0.001). Of patients with a clinically significant score at 24 hours, 71% had suffered a complication vs 11% of those without a clinically significant score (P <0.0001). The median nausea visual analogue scale scores at four hours were 69 mm (interquartile range 69 to 76 mm) in patients with a clinically significant score vs 0 mm (0 to 9 mm) in patients without a clinically significant score (mean difference 56 mm, 95% confidence interval 41 to 72 mm, P <0.0001).
The PONV Intensity Scale is a valid, responsive and practically useful instrument in distinguishing trivial from clinically significant PONV. The rate of clinically important PONV is considerably lower than the rate of any PONV symptoms perioperatively.
an attempt to guide clinical practice with the best available evidence 14 . This includes administration of antiemetic prophylaxis in patients assessed as being at increased risk of PONV, or for whom PONV would be a particularly undesirable outcome. This study also assessed the degree of compliance with published guidelines in our hospital.
MATERIALS AND METHODS
Following ethics committee approval, written informed consent was obtained from women undergoing gynaecological surgery at The Royal Women's Hospital, Melbourne, Victoria. This was a prospective cohort study. Inclusion criteria were gynaecological surgery, age 18 years or more and availability to participate in an interview at 24 hours postoperatively. Exclusion criteria were inadequate English comprehension, or intellectual or psychiatric disability preventing informed consent being obtained. Recruitment occurred across a four-month period.
Conduct of study
Consent was obtained either preoperatively or postoperatively before the first postoperative interview. Anaesthesia was conducted according to the attending anaesthetist's preference. Data collection occurred at four hours postoperatively for inpatients or when the patient was considered fit for hospital discharge for day-stay patients. Data collected included smoking status, history of PONV or motion sickness and preoperative antiemetic use. The Apfel simplified risk score 10 was calculated. Patients were asked to score pain on a 10-point verbal numerical rating scale and nausea on a 100 mm visual analogue scale (VAS). Vomiting, which can be objectively measured, was recorded as the total number of patients who vomited and the number of vomits. The PONV Intensity Scale 13 was then administered and the time taken to complete the score was noted. A PONV Intensity Scale score of 50 was defined as clinically significant PONV 13 . Clinical care was not altered by the administration of the PONV Intensity Score and the result was not available to treating staff. Details of the anaesthetic technique, including medications administered for PONV prophylaxis, were recorded from the anaesthetic record, and postoperative opioid analgesics and antiemetics were recorded from the medication chart. The durations of surgery and anaesthesia were obtained from the computerised theatre management system. Surgery was considered to be "major" if expected surgical time was >1 hour and planned inpatient stay was >1 night, or if patient-controlled analgesia was planned. Surgery was considered to be "minor" if expected surgical time was <1 hour and planned inpatient stay was one night, and no patientcontrolled analgesia was planned. Patients were included in the "day-stay" group if their discharge occurred on the same day as surgery, regardless of surgical duration, and all patients in this group had to tolerate oral intake and be comfortable on oral analgesia prior to hospital discharge.
Patients were re-interviewed 24 hours postoperatively, in person for inpatients or via phone for day-stay patients. Day-stay patients were questioned while the inpatients' medication chart was inspected concerning antiemetic medication. Enquires were also made about complications related to PONV, including inability to tolerate fluids or solids, inability to mobilise, wound dehiscence and pneumothorax. The need for intravenous fluids was assessed for inpatients. The PONV Intensity Scale was then administered.
Statistical analysis
Categorical data were summarised using number (%). Continuous data were assessed for normality. Normally distributed data were summarised using mean (standard deviation) and skewed data were summarised using median (range, interquartile range). Confidence intervals (95%) are reported where applicable. The relationship between the Apfel score and number of prophylactic antiemetics administered was assessed using the chi-squared test.
The validity of the PONV Intensity Scale was assessed by correlation between the Scale and the nausea VAS score (using Spearman rank correlation) and by the mean difference in the nausea VAS for those with a clinically significant and a clinically insignificant PONV Intensity Scale score (using a two-tailed unpaired t-test). Validity was also assessed by comparing the incidence of complications in patients with and without a clinically significant PONV Intensity Scale score, and by analysing antiemetic use in patients with and without a clinically significant PONV Intensity Scale score (using the chi-squared test).
The responsiveness of the Scale was assessed by quantifying the relationship between a change in PONV Intensity Scale score and a change in PONV symptoms (using chi-squared testing). The outcomes of interest were PONV Intensity Scale scores at four hours and at 24 hours postoperatively, and the antiemetic use and complications reported over this time.
The time to complete the PONV Intensity Scale was recorded as an indicator of the ease of use in clinical research practice, practical utility. All statistical analyses were performed in the statistical software package STATA (Stata Corporation, College Station, Texas, USA, version 10.0).
RESULTS
Seventy-six patients consented to participation and 73 patients completed data collection (one surgery cancellation, one discharge from the day surgery unit prior to the first interview and one loss to follow up for the 24-hour interview). Data from these three patients were excluded from further analysis.
Apfel scores of 3 to 4 were recorded for 76% of patients, representing moderate to severe risk of PONV (Table 1 ). Most patients received volatilebased general anaesthesia and only one patient was administered nitrous oxide ( Table 2 ). The two patients who received propofol-based general anaesthesia had Apfel scores of 4 ( Table 2 ). Sixty (82%) patients received prophylactic antiemetics (1=32 [43%], 2=26 [36%], 3=2 [3%]), but two or more antiemetics were administered to only 39% of the participants. The Apfel score did not predict the number of prophylactic antiemetics administered (P=0.42). Postoperative antiemetic treatment with one or more agents was charted for all patients.
At the four-hour interview, the median pain score was 2 (range 0 to 8), the median nausea VAS score was 0 mm (range 0 to 82 mm) and the median PONV Intensity Scale score was 0 (range 0 to 100). A clinically significant PONV Intensity Scale score was recorded by five patients (7%) at this interview. Thirty-four patients (47%) reported some nausea and four (12%) of these reported that nausea was present all the time. Eight of the 73 patients (11%) experienced some vomiting or dry retching, but only one (1.4% overall, 12.5% of those reporting vomiting) experienced more than three vomits. The median time taken to complete the PONV Intensity Scale at the four-hour interview was one minute (range one to three minutes).
At the 24-hour interview, the median PONV Intensity Scale score was 0 (range 0 to 600) and seven patients (10%) had clinically significant PONV. Of these, two also had clinically significant PONV at the four-hour interview. Some nausea was reported by 33 patients (45%) and three (9%) of these reported that nausea was present all the time. Vomiting or retching was experienced by 11 patients The Apfel score has a minimum score of 0 and a maximum score of 410. Age data presented as mean (range) and categorical data as number (%). ASA=American Society of Anesthesiologists, PONV=postoperative nausea and vomiting. (15%) by the 24-hour interview and four of these (5.5% overall, 36% of those vomiting) experienced more than three vomits. Therefore, in total, 10 patients (14%) had a clinically significant PONV Intensity Scale score, 42 (58%) reported nausea and 15 (21%) reported vomiting during the 24-hour period of this study. The Apfel scores and antiemetic prophylaxis administered to those participants who had clinically important PONV, as defined by the PONV Intensity Scale, at some time during this study are shown in Table 3 .
Antiemetic treatment had been administered to 16 patients (22%) by 24 hours postoperatively (17% of day-stay patients, 20% of minor cases and 29% of major cases). At 24 hours, four of the five patients (80%) with a clinically significant PONV Intensity Scale score at the four-hour interview had received antiemetic treatment compared to 18% of those with a clinically insignificant score (P=0.001). Similarly, at 24 hours, four of the seven patients (57%) with clinically significant PONV at the 24hour interview had received antiemetic treatment compared to 18% of those with clinically insignificant PONV (P=0.018).
Complications related to PONV (requiring intravenous fluids=2, not tolerating fluid=3 or food=10, being bedridden=4 or a combination of these=5) were reported by 12 patients (16%). The complication rates of those with and without clinically significant PONV at the four-hour interview were similar (20% vs 16%, P=0.82). However, of those with a clinically significant PONV Intensity Scale score at the 24 hour interview, 71% had suffered a complication compared to 11% of those with a clinically insignificant score (P <0.0001).
The median nausea VAS score among those with a clinically significant PONV Intensity Scale score at the four-hour interview was 69 mm (interquartile range 69 to 76 mm) and among those with a clinically insignificant PONV Intensity Scale score it was 0 mm (0 to 9 mm) (mean difference=56 mm, 95% confidence interval 41 to 72 mm; P <0.0001). The Spearman rank correlation coefficient for the nausea VAS score and the four-hour PONV Intensity Scale score was 0.7784 (P <0.0001). Of those with clinically significant PONV Intensity Scale scores at the four-hour interview (n=5), three (60%) had no vomiting and two (40%) had vomited. This compared to those with clinically insignificant PONV (n=68) where 62 (91%) had no vomiting and six (9%) had vomited (P=0.031). Of those with significant PONV (n=7) at the 24 hour interview, three (43%) reported no vomiting between interviews and four (57%) reported vomiting. In comparison, for those with a clinically insignificant PONV Intensity Scale score (n=66), 59 (89%) reported no vomiting and seven (11%) reported vomiting at least once (P=0.001).
DISCUSSION
The aim of our study was to test the validity, responsiveness and clinical utility of the PONV Intensity Scale in a gynaecological patient population. We confirmed our hypotheses in all respects and conclude that the PONV Intensity Scale is a useful clinical and research tool in gynaecological patients.
Validity was supported by the correlation of the PONV Intensity Scale score with the nausea VAS at the four-hour interview, indicating that a higher score was associated with a greater experience of nausea postoperatively. A clinically important PONV Intensity Scale score was also significantly related to the incidence of vomiting at the fourhour and 24-hour time points, which supports vomiting occurrence being associated with a greater experience of PONV and so validity of the scale. A clinically significant PONV Intensity Scale score at 24-hours was strongly associated with PONV-related complications, which supports the construct validity of the score in detecting clinically important PONV. Validity was further supported by antiemetic use by 24 hours being associated with a clinically significant score at the four-hour interview.
Only two of the patients with a clinically significant PONV Intensity Scale score at the four-hour interview also had a clinically significant score at the 24-hour interview, indicating a change in clinical status over time. Those with a clinically significant PONV Intensity Scale score at four hours received significantly more antiemetic treatment. Some of these patients did not have clinically significant PONV at 24 hours, indicating a treatment effect. Conversely, some patients with clinically insignificant PONV at the four-hour interview, who were less likely to receive antiemetics, then had significant PONV at the 24-hour interview, representing a later presentation of PONV. Similarly, clinically significant PONV at the four-hour interview was not associated with complications at 24 hours, presumably because symptoms then settled in some patients, allowing a return to normal function. However, those that developed clinically important PONV by the 24-hour interview were significantly more likely to report complications than those with a clinically insignificant PONV (P <0.0001). This supports the PONV Intensity Scale's ability to detect a change in clinical status over time and therefore display responsiveness. The utility of the PONV Intensity Score in clinical research was confirmed by a short administration time but further investigation and assessment of appropriateness would be required before consideration is given to its use in clinical practice.
Our study population was at high risk of PONV by Apfel criteria 10 and suffered high rates of nausea and vomiting postoperatively. Clinically important PONV, as defined by a PONV Intensity Scale score of 50 13 , was recorded in 10 patients (14%) in the first 24 hours postoperatively, which is similar to the rate of clinically important PONV reported in a general surgical population by the developers of the PONV Intensity Scale 13 . Nausea of some form was reported by the majority of the gynaecological surgery patients in this study (58%) and vomiting or retching was experienced by 21%, which is consistent with the high Apfel scores recorded in this cohort. Therefore, clinically important PONV was much less common than any PONV symptoms in this study, which is expected if the PONV Intensity Scale is able to discriminate between trivial and clinically important PONV.
Despite the risk of PONV being greater than 60% for 76% of the cohort studied 10 , increased antiemetic prophylaxis interventions were not applied to those with higher Apfel scores. Additionally, two or more antiemetics were administered to only 29 (39%) of the participants, despite recent evidence-based guidelines 14 supporting combination therapy in ambulatory surgery patients at high baseline risk of PONV. Antiemetic rescue was prescribed for all patients, but in our hospital this is a requirement for hand-over of care to recovery nursing staff, so it may not reflect the anaesthetist's assessment of the need for PONV rescue therapy.
This study has several limitations. The time period of assessment was limited to 24 hours and so some patients presenting with late PONV symptoms may have been missed. Extending the period of study to 48 or 72 hours would capture these patients. The anaesthetic techniques employed in this cohort were limited, with few patients receiving regional anaesthesia or propofol-based general anaesthesia, so these findings may not be able to be generalised to patients anaesthetised with those techniques. As the rate of clinically important PONV was considerably lower than the reporting of any PONV symptoms, a larger study which captured more patients with clinically important PONV would allow further exploration of the factors associated with clinically important PONV. The sample size of 73 was a convenience sample due to the rotation of one of the investigators (MA). However, given that the initial testing of the PONV Intensity Scale involved 163 patients from a variety of surgical fields 13 , the sample we report having gynaecological surgery is a useful initial step in the validation of this instrument in specific surgical populations. The high proportion of day-stay patients in this study (33%) makes interpretation difficult as many would not have had access to antiemetic medications if they experienced significant symptoms after discharge home. The sample size also limited the value of findings in relation to compliance with published PONV prophylaxis guidelines, and these findings may not be reflective of the practice of the whole hospital.
Future directions include assessment of the PONV Intensity Score in larger groups of patients undergoing procedures in a variety of subspecialty areas. Evaluation in a larger sample undergoing gynaecological surgery would be useful, given the low incidence of clinically significant PONV detected in this study. Potential improvements in clinical outcome could be assessed in a larger study where patients are randomised to assessment with the PONV Intensity Score or conventional measures. A role for this tool in clinical practice may be established if benefit was demonstrated and practical utility maintained.
In conclusion, within the limits of validity and responsiveness testing so far conducted, the PONV Intensity Scale performs well in the ability to detect clinically important PONV in the early postoperative period and reflect changes in clinical status over time.Clinically important PONV, as defined by the new measurement tool the PONV Intensity
